SPORE in Gastrointestinal Cancer

胃肠癌中的孢子

• 批准号: 7500963
• 负责人: Michael A. Hollingsworth
• 金额: $ 106.67万
• 依托单位: UNIVERSITY OF NEBRASKA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-05 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7500963
• 关键词: SPORE; Gastrointestinal; Cancer

DESCRIPTION (provided by applicant): This application for a Specialized Program of Research Excellence in Gastrointestinal (Pancreatic Cancer) will focus on translational studies that address basic and clinical issues of importance to improving the outcome of patients with pancreatic cancer. Specifically, the research projects in this program seek to: 1) develop and test novel diagnostic reagents and assays that will improve our ability to detect pancreatic cancer in its early stages; 2) develop and test novel therapeutic strategies including immunotherapy, chemotherapy, and chemoradiation therapy for patients with early and advanced pancreatic cancer; 3) undertake basic research studies in conjunction with clinical trials that will provide insight at the molecular level into the reasons for success and failure of the different strategies. The proposed SPORE program is focused on 4 projects with the high potential translational impact, and there are 2 highly interactive cores that will continue to acquire, store, and make available a unique set of tissue samples, data (clinical, molecular genetic, biological, pathological), reagents and resources: Project 1: Immunotherapy of Pancreatic Adenocarcinoma Project 2: Inhibitors of N-cadherin in the treatment of pancreatic cancer. Project 3: Biological marker(s) in the diagnosis of pancreatic cancer Project 4: Inhibitors of Telomerase in treatment of pancreatic adenocarcinoma Core 1: Administration Core 2: Pancreas Tumor SPORE Tissue Bank .

描述（由申请人提供）：本申请的胃肠道（胰腺癌）卓越研究专业计划将侧重于转化研究，解决对改善胰腺癌患者预后具有重要意义的基础和临床问题。具体而言，该项目的研究项目旨在：1）开发和测试新型诊断试剂和检测方法，以提高我们在早期阶段检测胰腺癌的能力; 2）开发和测试新型治疗策略，包括免疫治疗，化疗和放化疗，用于早期和晚期胰腺癌患者; 3）开展基础研究和临床试验，以便在分子水平上深入了解不同战略成功和失败的原因。拟议的SPORE计划侧重于4个具有高潜在转化影响的项目，有2个高度互动的核心将继续采集、存储和提供一套独特的组织样本、数据和信息。（临床、分子遗传学、生物学、病理学）、试剂及资源：项目1：胰腺癌免疫治疗项目2：N-钙粘蛋白抑制剂治疗胰腺癌。项目三：胰腺癌诊断中的生物标志物项目4：端粒酶抑制剂治疗胰腺癌核心1：管理核心2：胰腺肿瘤孢子组织库。